Anlotinib plus camrelizumab achieved long‐term survival in a patient with metastatic esophageal neuroendocrine carcinoma

BACKGROUND: Esophageal neuroendocrine carcinoma (NEC) is a rare cancer with an extremely poor prognosis. The average overall survival of patients with metastatic disease is only 1 year. The efficacy of anti‐angiogenic agents combined with immune checkpoint inhibitors remains unknown. CASE PRESENTATI...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Lingxiao, Xu, Guanxin, Chen, Tianwei, Wang, Qiyuan, Zhao, Jing, Zhang, Ting, Duan, Rong, Xia, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480405/
https://www.ncbi.nlm.nih.gov/pubmed/37381647
http://dx.doi.org/10.1002/cnr2.1855

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480405/
https://www.ncbi.nlm.nih.gov/pubmed/37381647
http://dx.doi.org/10.1002/cnr2.1855

Ejemplares similares